developed Dimer‐YL, a bispecific aptamer agonist targeting epidermal growth factor receptor (EGFR), which exhibited therapeutic effects in ulcerative colitis (UC) models (Figure 4c).[85] To further enhance in vivo stability and efficacy, cyclization strategies have been employed. Here, EGFR is linked to ulcerative colitis.